Directorate Change

TYRATECH, INC.

("TyraTech" or the "Company")

Directorate Change

TyraTech, Inc. (AIM: TYR), a natural life sciences company, announces that, Dr. Kevin Schultz, the Company's Chief Scientific Officer, will step down from his current role at the Company with effect from 1 April 2012 and will be appointed as a Non-Executive Director of the Company with effect from 1 April 2012.

Prior to joining TyraTech in August 2010, Dr. Schultz held numerous executive level positions with leading animal health organizations, including Merck & Co., Inc and Merial Limited where he was Chief Scientific Officer. Dr. Schultz received his Doctor of Veterinary Medicine from Purdue University and earned a Ph.D. from the University of Florida Medical School before joining Harvard Medical School and Harvard School of Public Health as a Fellow in Cancer Biology. Dr Schultz is a Venture Fellow for the Georgia Research Alliance.

All research and development activities for the Company will now be under the oversight of Dr. Keith Kennedy, Vice President Product Development.

Alan Reade, Executive Chairman of the Company, commented:

"We would like to thank Kevin for his time as TyraTech's Chief Scientific Officer and we are pleased to welcome him onto the Board. Kevin has a wealth of experience and expertise in the life sciences sector which we are delighted to be able to continue to draw upon."

Dr. Kevin Thomas Schultz, aged 60, does not currently hold, nor has held in the past five years, any other directorships.

Dr. Schultz holds a total of 200,000 Stock Appreciation Rights over common shares in the Company with a par value of US$0.001.

There is no other information regarding Dr. Schultz that is required to be disclosed pursuant to Schedule 2 (g) of the AIM Rules for Companies.

For further information please contact:

TyraTech Inc.

Alan Reade, Executive Chairman

Tel: +1 919 415 4310

Peter Jerome, Chief Financial Officer

Tel: +1 919 415 4280

N+1 Brewin, Nominated Adviser and Joint Broker

Robert Beenstock

Tel: +44 20 3201 3170

First Columbus LLP, Joint Broker

Chris Crawford

Tel: 020 3002 2070